MNKD: MannKind Corp. Company Value to Net Income

Corporate emblem and logo of MannKind Corp (MNKD)

Growing demand for inhalable diabetes therapy is expanding the consumer base for MannKind Corporation (MNKD). The company's earnings multiple visualizes the business valuation trend, where -17.70 forms the current metric. However, geopolitical risks and sanctions limit access to several markets. Stability of supply is ensured by its own high-tech plant in Connecticut, which guarantees sterility and full production control.

MNKD Afrezza: Price to Earnings Ratio in the range 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for MannKind Corp (MNKD)

- price and consensus price forecast:
- market capitalization information:
Comprehensive company analysis:MannKind Corp - MNKD
Flagship merchandise of MannKind

The supply chain management efficiency of MannKind Corporation (MNKD) inhalation systems is directly reflected in the company's P/E chart, which compares current market capitalization with net income. Analyzing this ratio allows for the determination of the asset's premium, assessing how many years it will take to achieve a return on investment assuming current profitability and the stability of long-term vendor contracts are maintained.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)